Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Shares Outstanding (Weighted Average): 2015-2025

Historic Shares Outstanding (Weighted Average) for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $8.8 million.

  • Seres Therapeutics' Shares Outstanding (Weighted Average) rose 15.40% to $8.8 million in Q3 2025 from the same period last year, while for Mar 2025 it was $8.7 million, marking a year-over-year increase of 15.46%. This contributed to the annual value of $8.5 million for FY2024, which is 32.09% up from last year.
  • Seres Therapeutics' Shares Outstanding (Weighted Average) amounted to $8.8 million in Q3 2025, which was up 0.25% from $8.7 million recorded in Q2 2025.
  • Seres Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $8.8 million for Q3 2025, and its period low was $4.6 million during Q1 2021.
  • For the 3-year period, Seres Therapeutics' Shares Outstanding (Weighted Average) averaged around $7.5 million, with its median value being $7.6 million (2024).
  • Data for Seres Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 38.68% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Shares Outstanding (Weighted Average) stood at $4.6 million in 2021, then soared by 35.65% to $6.2 million in 2022, then increased by 3.74% to $6.5 million in 2023, then skyrocketed by 32.09% to $8.5 million in 2024, then climbed by 15.40% to $8.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $8.8 million for Q3 2025, versus $8.7 million for Q2 2025 and $8.7 million for Q1 2025.